• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search
Home » Clinical Trials » RBX2660 Clinical Trials

RBX2660 Clinical Trials

Rebiotix Inc., a Ferring Company, has conducted several trials of the lead microbiota-based product in the MRT™ drug platform, RBX2660, for reducing the rate of recurrence of Clostridioides difficile infection. RBX2660 is currently under study in a Phase 3 clinical trial in conjunction with the US Food and Drug Administration’s Investigational New Drug application, as well as the Clinical Trial Application (CTA) of HealthCanada. The following sections outline the studies conducted to date:

Study: PUNCH CD3-OLS (Currently Enrolling)

About

The PUNCH CD3-OLS study is a Phase 3 clinical study to assess the safety and tolerability of Rebiotix RBX2660 for the prevention of recurrent Clostridioides difficile infection (CDI) in a recurrent CDI population that is broader and more inclusive than that included in prior studies using RBX2660.

  • Prospective, multi-center, open label Phase 3 study
  • Enrolling up to 600 patients at approximately 80 research sites
  • Primary efficacy endpoint: Assess the efficacy of RBX2660 defined as no CDI recurrence at 8 weeks
  • Primary Safety endpoint: Assess the safety of RBX2660 to 6 months

Detailed Information & Site Locations

Visit: clinicaltrials.gov

Study Participation

Email: US8-StudyInfo@nullferring.com

Study: PUNCH CD3 (Active, Not Enrolling)

About

The PUNCH CD3 study is a Phase 3 clinical study to evaluate the safety and efficacy of Rebiotix RBX2660 for the prevention of recurrent Clostridioides difficile infection (CDI).

  • Prospective, randomized, double-blind, placebo-controlled study
  • Enrolling up 270 patients at approximately 60 research sites in US and Canada
  • Randomized to receive RBX2660 or placebo (2:1)
  • Primary efficacy endpoint: Assess the efficacy of RBX2660 defined as no CDI recurrence at 8 weeks as compared to placebo
  • Primary safety endpoint: Assess the safety of RBX2660 to 6 months

Detailed Information & Site Locations

Visit: clinicaltrials.gov

Study: PUNCH Open Label (Completed)

About

  • Prospective, multicenter, open-label, controlled Phase 2 study
  • Primary efficacy endpoint involved a comparison of patients treated with RBX2660 to a closely matched set of antibiotic only treated historical controls through 56 days
  • 31 active treatment sites and four control sites in the U.S. and Canada.
  • 132 RBX2660 and 110 historical control subjects were included in this topline analysis

Results

  • Topline results reported in March 2022

Study: PUNCH CD2 (Completed)

About

  • Phase 2B, prospective, multi-center randomized double-blind, placebo-controlled with 2-year follow-up
  • Primary efficacy objective: Assess the efficacy of RBX2660 vs. placebo defined as no CDI recurrence at 8 weeks
  • Primary safety objective: Assess the safety of RBX2660
  • A total of 120 patients enrolled at 21 sites in the U.S. and Canada
  • Patients were randomized into 3 treatment arms

Results

  • Presented at Fall Conference in 2016

Study: PUNCH CD (Completed)

About

  • Phase 2 prospective multi-center, open-label study with 6-month follow-up
  • Primary objective: Assess the safety of RBX2660
  • Secondary objective: Efficacy defined as no CDI recurrence at 8 weeks

Results

  • Forty patients were enrolled at 11 centers in the US; a total of 31 patients completed 6-month follow-up.
  • Overall efficacy was 87.1% (27/31).
  • Safety: Most commonly reported AEs were mild to moderate diarrhea, flatulence, abdominal pain/cramping and constipation and were self-limiting.
  • Twenty serious AEs were reported in 7 patients; none were related to RBX2660 or its administration.
  • Results on clinicaltrials.gov
  • Results published November, 2015

Conclusions

  • RBX2660 demonstrated a satisfactory safety profile in a Phase 2 study targeted at recurrent CDI which included a rigorous, independent assessment of AEs.
  • Overall efficacy of 87.1% is in line with previously reported results.

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT